

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jul 2026

Fasted-state in vivo bioequivalence study of Mexiletine 200 mg capsule manufactured by Alborz Co. compared with innovator product

Protocol summary

Study aim

In vivo bioequivalence study of Mexiletine 200 mg capsule

Design

The clinical trial has control and test groups with crossover, randomized design, without blinding. Twenty-four healthy volunteers will participate randomly in the study as two twelve-person study groups. Each volunteer will receive a single dose of drug in two periods. In one period the test formulation and in another period the reference formulation. Therefore, each volunteer will be his own "Control". To randomly assign participants in two groups, the lottery method will be used.

Settings and conduct

After oral administration of 200 mg capsule to volunteer, the blood samples will be collected in predetermined time intervals up to 48 hours. The samples will be stored in freezer -4 degrees centigrade until analysis and sample quantitation. The concentration of drug in blood samples will be measured by liquid chromatography. The study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences.

Participants/Inclusion and exclusion criteria

Inclusion criteria: General Health (in terms of Liver, Heart and Kidney), Age (18-59 years old) Exclusion criteria: Smoking, History of cardiovascular, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy.

Intervention groups

Intervention group will receive a single oral dose of test drug product (Mexiletine 200 mg capsule manufactured by Alborz) and Control group will receive a single dose of reference drug product (Mexiletine 200 mg capsule manufactured in Canada). Blood samples will be taken for 48 hours at the mentioned time points after drug administration and the plasma will be stored in freezer until analysis. In both groups, breakfast and lunch will be served two and six hours after drug administration, respectively.

Main outcome variables

Drug plasma concentration

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210519051345N46**

Registration date: **2024-01-24, 1402/11/04**

Registration timing: **prospective**

Last update: **2024-01-24, 1402/11/04**

Update count: **0**

Registration date

2024-01-24, 1402/11/04

Registrant information

Name

Parvin Zakeri-Milani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3334 8801

Email address

pzakeri@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-02-04, 1402/11/15

Expected recruitment end date

2024-10-06, 1403/07/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Fasted-state in vivo bioequivalence study of Mexiletine 200 mg capsule manufactured by Alborz Co. compared with innovator product

Public title

Investigating Bioequivalence of Mexiletine 200 mg Capsule compared to innovator product

Purpose

Other

Inclusion/Exclusion criteria**Inclusion criteria:**

General Health (in terms of Liver, Heart and Kidney), Age (18-59 years)

Exclusion criteria:

Smoking, History of cardiovascular disease, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy

Age

From **18 years** old to **59 years** old

Gender

Male

Phase

Bioequivalence

Groups that have been masked

No information

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

Randomized

Randomization description

To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Crossover

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Biomedical Research Committee, Tabriz University of

Medical Sciences

Street address

Biomedical Research Committee, Tabriz University of Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Approval date

2024-01-14, 1402/10/24

Ethics committee reference number

IR.TBZMED.REC.1402.776

Health conditions studied**1****Description of health condition studied**

In the present study, the products will be administered to healthy volunteers

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Plasma concentration of drug

Timepoint

0.5-48 hours in predetermined time intervals after drug administration

Method of measurement

HPLC (High performance liquid chromatography)

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: Intervention group will receive a single oral dose of test product (Mexiletine 200 mg capsule manufactured by Alborz) in fasted state. Blood samples will be collected for 48 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively

Category

Treatment - Drugs

2**Description**

Control group: Control group will receive a single oral dose of reference product (Mexiletine 200 mg capsule

manufactured in Canada) in fasted state. Blood samples will be collected for 48 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Faculty of Pharmacy, Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori St., Golgasht St.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parviz Shahabi

Street address

No.2 Central Building 3rd Floor, Tabriz University of Medical Sciences, Daneshgah St.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

shahabip@tbzmed.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

Alborz Company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori St., Golgasht St.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori St., Golgasht St.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone
+98 41 3334 8801
Email
pzakeri@tbzmed.ac.ir

51664-14766
Phone
+98 41 3334 8801
Email
pzakeri@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Zakeri-Milani
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori St., Golgasht St.
City
Tabriz
Province
East Azarbaijan
Postal code

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable